TRASTUZUMAB (ONTRUZANT) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Highmark reviews TRASTUZUMAB (ONTRUZANT) prior authorizations against its medical policy for HER2/neu Receptor Antagonist [EPC]. The FDA-approved indication (2019) is POWDER. Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Highmark's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
If the PA is denied
Highmark gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus a peer-reviewed citation supporting TRASTUZUMAB (ONTRUZANT)for the patient's indication.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for TRASTUZUMAB (ONTRUZANT) prior auth?
Highmark's typical PA packet for TRASTUZUMAB (ONTRUZANT): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Highmark?
Standard TRASTUZUMAB (ONTRUZANT) PA decisions at Highmark: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Highmark most often reject TRASTUZUMAB (ONTRUZANT) for?
Across Highmark's book the common rejection patterns include: Prior auth on biologics; PA on advanced imaging; OON balance bills. For TRASTUZUMAB (ONTRUZANT) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Highmark on TRASTUZUMAB (ONTRUZANT)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the TRASTUZUMAB (ONTRUZANT) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (ONTRUZANT) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com